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Over years, the regular use of cannabis has substantially increased among young
adults, as indicated by the rise in cannabis use disorder (CUD), with an estimated
prevalence of 8. 3% in the United States. Research shows that exposure to
cannabis is associated with hypodopaminergic anhedonia (depression), cognitive
decline, poor memory, inattention, impaired learning performance, reduced dopamine
brain response-associated emotionality, and increased addiction severity in young
adults. The addiction medicine community is increasing concern because of the
high content of delta-9-tetrahydrocannabinol (THC) currently found in oral and vaping
cannabis products, the cognitive effects of cannabis may become more pronounced
in young adults who use these cannabis products. Preliminary research suggests
that it is possible to induce ’dopamine homeostasis,’ that is, restore dopamine
function with dopamine upregulation with the proposed compound and normalize
behavior in chronic cannabis users with cannabis-induced hypodopaminergic anhedonia
(depression) and cognitive decline. This psychological, neurobiological, anatomical,
genetic, and epigenetic research also could provide evidence to use for the development
of an appropriate policy regarding the decriminalization of cannabis for recreational use.
Keywords: cannabis use disorder, depression, anhedonia, neuroanatomic alterations, reward deficiency
syndrome, genetic testing, pro-dopamine regulation, dopamine homeostasis
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PREVALENCE
Cannabis is regarded as the most abused illicit drug in the
world today. An estimated 150–200 million people use cannabis
regularly, and a relatively common disorder, known as cannabis
use disorder (CUD), has an estimated prevalence of 8.3% in
young adults in the United States (1, 2). A recent survey of
482 young college students, ∼19–20 years, found that 29% of
students vaped cannabis. From this survey, men from high
socioeconomic status (SES) vaped higher cannabis amounts than
men 13–14 years from lower SES status and women (3). Between
2000 and 2016, the lifetime and daily use of cannabis among
12th graders was 44 and 6%, respectively. In 2019, 8th graders’
∼13–14 years, past-year use was 11.8%, and past-month use was
6.6%, 28.8% of 10th graders had used marijuana in the past year
and 18.4% in the past month. Among 12th graders, ∼17–18
years, rates of cannabis use grew to 35.7% during the previous
year and 22.3% in the previous month. Reports of daily and
near-daily use were 6.4%. Almost 4% of 12th grader teens vape
cannabis products daily (NIHWhat is the scope of marijuana use
in the United States? Marijuana Research Report, https://www.
drugabuse.gov/ [accessed October 28, 2020]).
More importantly, there is increasing concern by the
addiction medicine community that because of the high content
of delta-9-tetrahydrocannabinol (19-THC), (the chemical that
causes the high) currently found in edibles and vaping cannabis
vaping products [up to 90%; https://www.marijuanabreak.com/
90-percent-thc-weed, (accessed January 20, 2020)], the chronic
cannabis users may develop more severe hypodopaminergic-
anhedonia (depression) and cognitive decline. Incidentally, other
serious respiratory and pulmonary consequences, including
chronic obstructive pulmonary disorder (COPD), have also been
reported among those who use e-vaping devices (4).
CANNABIS AND NEUROANATOMIC
ALTERATIONS AND COGNITION
Cannabidiol (CBD) can ameliorate the effects of THC and protect
the brain from damages, possibly through CB1 antagonism
(5). These psychophysiological damages include dose-dependent
psychotic cognitive and behavioral symptoms (6) and observed
from several human structural neuroimaging studies frequency
of use dependent reductions in gray matter volumes. The
reductions occur in the medial temporal cortex, orbitofrontal
cortex, temporal poles, parahippocampal gyrus, and insula.
Chronic cannabis users also display significant neuroanatomic
alterations in the medial temporal, frontal cortex, cerebellum (7),
and the fusiform gyrus, temporal pole, superior temporal gyrus,
and occipital cortex (8).
A top area of concern, especially in young developing
adults, is the damaging effect of high doses of 19-THC and
consequent cognitive impairment. According to Floresco et al.
(9) and Lorenzetti et al. (8), the neuroanatomic alterations
in the prefrontal-hippocampal function and subsequent
down-regulation of CB1 receptors may result in cognitive
decline/working memory, decision-making, and inhibitory
control in chronic cannabis users. Cannabinoid type 1
receptors (CB1) associated with motivational, emotional,
and affective processing (10) are usually abundant in these
areas, so upregulation of CBD1 receptors may positively affect
THC-induced brain damage. Notably, these cognitive effects may





In adult cannabis users, brain activation decreases in the middle
temporal gyrus, insula, and striate area and increases in the
superior and posterior transverse temporal and inferior frontal
gyri and middle temporal gyrus. While activation in adolescents
increases in the inferior parietal gyrus and putamen compared
to healthy controls (13). Research suggests that functional
alterations in these areas are neuroadaptive changes in cannabis
users and may be compensatory (13).
CANNABIS AND DOPAMINERGIC
FUNCTION
Chronic cannabis usage, including in adolescents, has also
significantly reduced striatal dopamine release causing
(hypodopaminergia) and associated poor memory, inattention,
and impaired learning performance (14). Chronic use of
cannabis observed with [18F]-DOPA PET found reduced
brain dopamine synthesis and subsequently attenuated reward
sensitivity, motivation, and induced apathy. It is noteworthy that
the 9/9 allele polymorphism carriers have high D2/D3 receptor
availability (due to higher dopamine re-absorption rates)
compared to carriers of the 10/10 alleles in early-onset heavy
cannabis users (15). The carriers of the 7R DRD4 polymorphism
are likely to experiment with cannabis more than the non-
carriers. According to Volkow et al. (16), among cannabis
users, there is a reduced dopamine brain response linked
to the emotionality and severity of the addiction. Cannabis
users also show inversely correlated dopamine reactivity with
higher negative emotionality scores relative to controls (17).
There is some evidence that suggests large doses of 19-THC
increase dopamine release by inhibiting VTA GABAergic activity
(18). This effect may translate to an increased fear reaction
in cannabis users. In animal experiments (19), the repeated
administration of 19-THC induced depressive-like symptoms,
including prolonged anhedonia due to CB1 type receptors’
impairment and dopaminergic alterations in the mesolimbic
region. This 19-THC induced dysfunction in animals associates
with attenuated anandamide signaling. Interestingly, the subjects
with CUD diagnosis and no baseline depressive symptoms were
at the follow-up, four times more likely (age-adjusted) to have
depressive symptoms than those with no CUD diagnosis (20).
In the past, the chronic use of cannabis of low potency (2–
4% 19-THC) did not associate with significant neuroanatomic
alterations, psychosis, or even depression. However, as the
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mean 19-THC concentration has increased substantially over
the last 10 years, from 8.9 to 17.1% by 2017 (21), the use of
cannabis products such as pastes, gummies, and e-vaping devices
with still higher concentrations of 19-THC, reported as high
as 90%, may result in a higher degree of hypodopaminergia,
associated poor memory, inattention, and impaired learning
performance in chronic cannabis users, especially among
adolescents with cannabis use disorder. Thus, the brain changes
and symptomatology that signify chronicity depend on potency
and duration, frequency of use; smoking cannabis daily multiple
times per day.
BALANCING DOPAMINE FUNCTION WITH
PRECISION PRO-DOPAMINE REGULATION
The functional neuroimaging techniques, such as resting-state
functional magnetic resonance imaging (rsfMRI), have shown
that acute exposure to cannabis reduces the neuronal activity
in the nucleus accumbens (NAc) and prefrontal cortex (PFC),
anterior cingulate gyrus (ACG), striatum, and thalamus. In
contrast, chronic cannabis exposure increases the rsfMRI in
these brain regions, and in adolescents’ chronic use of high
19-THC content cannabis results in impaired motivation with
depression, anhedonia, low academic achievement, and reduced
functional connectivity in the brain reward circuitry (22, 23).
The primary neurochemical insult is an altered dopaminergic
function across mesolimbic pathways requiring neurotransmitter
balance across the brain reward system. Nestor et al. (24) found
that in chronic cannabis users (with an average of 6.1 [range =
2.5–17] lifetime years of cannabis use and with the consumption
of 7,258-lifetime cannabis joints), there is an increased ventral
striatal (VS) blood-oxygen-level-dependent (BOLD) response to
stimuli predicted potential non-drug rewards. Importantly, VS
hyperactivity is seen during reward anticipation associated with
years of cannabis use and the lifetime estimation of numbers of
cannabis joints consumed. Another known impairment related
to chronic cannabis use relates to compulsive drug use with
NMDA receptor-dependent synaptic depression located at the
ventral tegmental area (VTA) linked to dopamine circuitry.
Chronic cannabis exposure also activates VTA cannabinoid CB1
receptors and reduces transient neurotransmission at VTA local
Glu-DA synapses by activating NMDA receptors and subsequent
endocytosis of AMPA receptor GluR2 subunits (25).
This evidence provides possible new targets in obviating
chronic addiction learning, specifically with chronic cannabis
use in humans. Dopamine augmentation is difficult to achieve,
especially after the development of a substance use disorder
(SUD). Vigorous physical exercise, like Eminem, TMS, and
nutraceuticals, have been proposed as viable options. Our
proposal herein of incorporating genetic risk allelic testing related
to reward pathways along with potential induction of dopamine
homeostasis seems logical. This concept takes on even more
importance when we consider that the onset and peak use of
cannabis occur during brain development in teenagers and, as
such, represents an unwanted window of liability (26, 27). The
onset of cannabis use begins in the mid-teens and peaks by the
age of 25, with the development of cannabis use disorder between
15 and 20. In order to either prevent or treat the high dose
19-THC-induced hypodopaminergic anhedonia and cognitive
decline, it may be possible to combine the non-invasive testing
for the genetic addiction risk score (GARS) with pro-dopamine
regulation and restore the dopamine function (26–58). A novel
model (Figure 1) espouses a reasonable biphasic approach;
a short-term blockade followed by long-term dopaminergic
upregulation with KB220Z∗ primarily for reward deficiency
syndrome (RDS) behaviors (29–38).
“∗KB220Z Components, The most recent variant of KB220Z
(powdered form), is composed of the following ingredients:
Vitamin B6, 10mg (500%); Thiamine, 15mg (1,033% of Daily
Value); and Chromium poly nicotinate, 200 mcg (166%). A
fixed-dose of synaptose is included as well, which is a combination
of amino acids and herbs that contains DL-Phenylalanine,
L-Tyrosine, Passion-Flower Extract; a Complex containing
Arabinogalactans, N-Acetylglucosamine, Astragalus, Aloe Vera,
Frankincense Resin, White Pine Bark Extract, and Spirulina;
Rhodiola; L-Glutamine; 5-Hydroxytryptophan (5-HTP);
Thiamine Hydrochloride; Pyroxidal-5-phosphate and Pyridoxine
HCl, CoQ10, NADH, and N-Acetyl Cysteine (NAC); (59). The
powder was manufactured by Cephram, Inc. (New Jersey)”.
However, in chronic cannabis-using adolescents, the goal
would be to enhance brain reward functional connectivity
[measures the degree of synchrony of the BOLD time-series
between different brain regions] and connectivity volume
[Voxel-based morphology (VBM)], attenuate depression-like
symptoms (anhedonia), and target stress-like anti-reward drug
dependence symptoms. Using fMRI of both naïve animals (60)
and heroin abstinent subjects (61), we confirmed blood-oxygen-
level-dependent (BOLD) activation of dopaminergic reward
pathways and recruitment of dopamine neuronal firing with
KB220Z. These types of fMRI results provide some evidence for
dopaminergic activation.
Millions of individuals worldwide struggle to combat their
frustrating and even fatal romance with getting high daily. The
neuroscience community conducts and funds incredible research
using sophisticated molecular-genetic applied technology in
animal experiments and humans using neuroimaging to
advance our understanding of brain reward circuitry’s complex
functions that play a vital role in the expressed symptoms
found in addictions. Although dopamine is known as a
major neurotransmitter involved in addictions, many disagree
about how to deal with dopamine dysregulation clinically
to prevent and treat addictive disorders, including cannabis
use disorder (CUD). An alternative approach could include
two phases; a brief blockade followed by stable dopaminergic
upregulation. The treatment goal would be to augment brain
reward functional connectivity volume by targeting reward
deficiency and the stress-like anti reward symptomatology of
addiction. These phenotypes can be characterized using the
Genetic Addiction Risk Score (GARS). Dopamine homeostasis
may thus be achieved via “Precision Addiction Management”
(PAM) R©, the customization of neuronutrient supplementation
based on the GARS test result, along with a behavioral
intervention (29).
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FIGURE 1 | It is a Model proposed for combatting chronic use of potent cannabis and anhedonia (Original figure Blum 2020). Note: Potency of cannabis may be as
high as 90% THC in gummies and vaping products.
Dopaminergic homeostasis could be achieved by genetic
testing for addiction risk and administering precursor amino
acid and enkephalinase inhibitory, non-addictive, natural
complex pro-dopamine regulator (KB220), matching to
one’s neurotransmitter pathways associated reward gene
polymorphisms, as previously proposed. Fried et al. (59)
reported a case series about the novel treatment of screening
with GARS and utilizing a customized pro-dopamine regulator
matched to polymorphic reward genes with a hypodopaminergic
risk. The proband was a female of 34 years with a history
of cannabis abuse and alcoholism. She voluntarily entered
treatment after experiencing a car accident while driving under
the influence. Following an assessment, she was genotyped using
the GARS and given a polymorphic matched neuro-nutrient
with a KB220Z base. She successfully recovered from Substance
Use Disorder (SUD) and experienced improved socialization,
family, economic status, well-being, and attenuation of major
depression. She tested urine negative over the first 2 months in
treatment and a recent screening. Following ∼2 months into
the program, her parents also decided to take the GARS and
started taking the recommended variants. The proband’s father
(a binge drinker) and mother (no SUD) showed improvement
in various behaviors. Finally, the proband’s biological children
were also GARS tested, showing a high risk for SUD. This
three-generation case series represents an example of the
impact of genetic information coupled with an appropriate
DNA guided “Pro-Dopamine Regulator” to recover and
enhance life.
Over the many years of the development of the putative pro-
dopamine regulator, with the research ID code of KB220Z, there
have been a plethora of studies showing remarkable benefits
related to reward deficiency behaviors and associated drug and
non-drug phenotypes (26, 27, 29, 51, 55, 56, 59, 60, 62–93).
This KB220Z variant has been the subject of at least
43 clinical and pre-clinical studies showing anti-RDS
addictive behaviors via dopaminergic mechanisms [see
Annotated Bibliography and review by Blum et al. (30)]
and Figure 2.
Manza et al. (94) suggest that chronic cannabis abuse is
associated with resting-state brain function changes, particularly
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FIGURE 2 | It is a schematic showing list of RDS benefits of KB220 variants Original figure Blum 2020.
in dopaminergic nuclei implicated in psychosis, habit formation,
and reward processing. Is it possible that by utilizing GARS-
guided precision, KB220Z could help restore the normal
functioning of reward processing and connectivity in cannabis-
using subjects, especially in our youth and high-risk populations?
ISSUES OF CANNABIS LEGALIZATION
Even though extensive research shows that chronic use of
cannabis is associated with significant adverse health effects
(16, 95–97), there is a disturbing trend of many states in the
United States (US), and other countries legalize cannabis for
unregulated recreational and medicinal use. Colorado was one
of the first two U.S. states to legalize cannabis for recreational
use for adults 21 and older. There are serious concerns regarding
physical and mental health risks, particularly among adolescents
whomay use cannabis of high THC content. According to Parnes
et al. (98), two hypotheses have been studied. First, cannabis use
among college students 21 years old and older would increase
after recreational legalization. Second, there would be a positive
correlation between the new cannabis legislation and out-of-
state students’ decision to attend a Colorado university as well as
their cannabis use after that. However, the opposite was found.
Data from a survey of 5,241 undergraduate students showed
that cannabis use increased since recreational legalization for all
students, particularly for those over 21 years. For past-month use
frequency, no differences were found between pre-legalization
and post-legalization (98).
Moreover, out-of-state students reported higher past 30-day
use than in-state students. Indeed, one real concern relates
to the post-legalization opening of retail cannabis stores and
adult cannabis use throughout the country. Specifically, Everson
et al. (99) evaluated this issue in Washington and found that
frequent cannabis use grew significantly between 2009 and
2016 with greater access to cannabis retailers. Frequent use
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increased among adults living within 0.8 miles of a retailer.
Moreover, Klimer (100) developed a 14-point policy as follows:
(1) Production, (2) Profit motive, (3) Power to regulate, (4)
Promotion, (5) Prevention and treatment, (6) Policing and
enforcement, (7) Penalties, (8) Prior criminal records, (9)
Product types, (10) Potency, (11) Purity, (12) Price, (13)
Preferences for licenses, and (14) Permanency. A crucial aspect
of moving forward in terms of legalization must address the high
content of THC in waxes and other products, as well as statewide
inconsistencies (101).
On the other hand, the American Society of Addiction
Medicine (ASAM) issued a policy statement (102) on marijuana
and cannabinoids, recommending decriminalization instead of
legalization of cannabis and cannabinoids. Furthermore, the
legalization of the commercial sale and promotion of cannabis
with high THC content for recreational use in many states
(Alaska, California, Colorado, Illinois, Maine, Massachusetts,
Michigan, Nevada, Oregon, Vermont, and Washington) may
lead to significant increases THC intoxication, dependence,
and addiction because of the euphoria. Consequently, the
neurochemical impact on reward systems in the brain that can
lead to neurological reward system deficits may also be significant
and of great concern to clinicians.
Thus, until an FDA-approved therapy for treating
cannabis use disorder and any of its adverse health
components, developing a safe and responsible strategy
toward decriminalizing cannabis and cannabis products seems
paramount in the United States. As such, consideration of using
KB220Z, a dopamine up-regulator discussed above, for restoring
balanced neurotransmission and alleviating hypodopaminergia
and its consequences like anhedonia (depression), cognitive
decline, and other mental health effects due to chronic cannabis
use. Similarly, the supplement N-acetylcysteine (NAC) to treat
substance use disorders, including CUD, could be useful. In a
double-blind, randomized control trial of a cohort of cannabis-
dependent adolescents, Gray et al. (103) demonstrated that NAC
is an effective treatment for cannabis use disorder, and Tomko
et al. (104) revied NAC as a potential treatment for substance use
disorders, including cannabis.
CONCLUSION
Although the prevalence of recreational cannabis users at high
risk for developing anhedonia and depression is unknown,
the amount of cannabis used (dose of THC) seems to be
an important factor. Chronic use of high THC content
cannabis, either by oral ingestion or vaping, results in reversible
neuroanatomic alterations in the mesolimbic and cortical brain
regions with subsequent hypodopaminergia and associated
depression/anhedonia. Cannabis use among young adults causes
these neuroanatomical and psychological changes, magnified
by DNA polymorphisms in pro-dopamine reward genes (like
DAT1, DRD2, DRD4, COMT). These DNA polymorphisms
can be measured either before cannabis use (prophylaxis) or
post-use (epigenetic). Treatment should involve the induction
of dopamine homeostasis via pro-dopamine regulation and
thereby ameliorate anhedonia. No FDA-approved therapies are
currently available to treat CUD or any comorbidities, such
as depression or cognitive decline (23, 58, 71, 94, 105–112).
Using a dopamine up-regulator such as KB220Z to restore
brain dopamine in hypodopaminergia until an FDA-approved
therapy is available could be considered for chronic cannabis
users with CUD. The development of an appropriate policy
regarding the legalization of cannabis and cannabis products and
decriminalization is needed.
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